Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $600.00 at Oppenheimer

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target upped by investment analysts at Oppenheimer from $540.00 to $600.00 in a research note issued on Tuesday, Marketbeat.com reports. The brokerage presently has an “outperform” rating on the pharmaceutical company’s stock. Oppenheimer’s price objective indicates a potential upside of 30.19% from the company’s previous close.

Several other research analysts have also recently issued reports on VRTX. Wells Fargo & Company upped their price objective on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Scotiabank increased their target price on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Morgan Stanley reissued an “overweight” rating and issued a $570.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. UBS Group increased their target price on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, HC Wainwright lifted their target price on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research note on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $548.73.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $460.87 on Tuesday. The company’s 50-day simple moving average is $467.50 and its 200 day simple moving average is $435.79. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.68. The company has a market capitalization of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.98 earnings per share. On average, analysts forecast that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Amit Sachdev sold 1,846 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $897,802.10. Following the completion of the transaction, the executive vice president owned 55,570 shares in the company, valued at $27,026,469.50. The trade was a 3.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 260 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $126,451.00. Following the completion of the transaction, the executive vice president owned 46,763 shares of the company’s stock, valued at $22,743,185.05. This trade represents a 0.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 91,156 shares of company stock valued at $42,845,497. 0.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Motiv8 Investments LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $26,000. Swiss RE Ltd. acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $28,000. Chesapeake Asset Management LLC boosted its position in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares during the period. Eagle Bay Advisors LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $29,000. Finally, IMG Wealth Management Inc. increased its stake in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER interim results met the primary and all secondary endpoints — Vertex reported strong Week 36 data showing povetacicept produced meaningful effects in adults with IgAN; the company described the readout as positive and the market reacted with after-hours buying. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Company and press reports say the data are strong enough that Vertex plans an FDA filing (reportedly by March) for povetacicept, and headlines emphasized a late-session/share pop — a clear near-term catalyst for upside if regulators agree on the path. Vertex (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results
• Positive Sentiment: Analysts reacted quickly: HC Wainwright raised its price target to $641 and kept a Buy rating; BMO Capital and William Blair reiterated Buy ratings with elevated targets (~$600 from BMO cited), reflecting expectations that povetacicept could be “best-in-class” in IgAN and add upside beyond Vertex’s cystic fibrosis cash flows. HC Wainwright price-target raise BMO / analyst coverage
• Neutral Sentiment: The RAINIER result cited is an interim analysis of an ongoing Phase 3 trial — strong interim data are encouraging but full trial readouts, regulatory review, and long-term safety/efficacy data remain to be confirmed. Investors should note the typical regulatory and commercialization execution risks. Yahoo Finance: Vertex interim analysis
• Negative Sentiment: Separately, Vertex’s most recent quarterly report showed a tiny EPS miss (reported 5.03 vs. 5.05 consensus) and, while revenue grew year-over-year, investors should weigh near-term valuation versus long-term pipeline upside. This older earnings miss could temper upside if pipeline approvals face delays. MarketBeat: VRTX profile / recent results

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.